LONDON (Alliance News) - Sareum Holdings PLC on Tuesday said the US Patent and Trademark Office and the European Patent Office have said patents will be granted for inventions associated to its Aurora+FLT3 Kinase Inhibitor Programme.
These patents cover compounds that inhibit the activity of Aurora and FLT3 kinase enzymes, particularly used in the treatment of cancer. The US patent is expected to be granted Tuesday, whilst the European patent will be granted subject to some formalities, shortly after next Friday.
Sareum expects similar patents to be granted in other markets, including Japan and China, in due course.
"These notifications of patent grants for Sareum in the USA and Europe demonstrate the strength of the intellectual property protecting our Aurora+FLT3 programme, and enhance our negotiating position with potential licensing partners," said Chief Scientific Officer John Reader in a statement.
Shares in Sareum were up 6.1% at 0.260 pence Tuesday morning.
By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews
Copyright 2015 Alliance News Limited. All Rights Reserved.
Sareum (SAR)